Sonavex is a Johns Hopkins spin-out founded in 2013 by David Narrow, Devin O’Brien-Coon, MD, MSE, and Jerry Prince, PhD. The company has developed a portfolio of novel ultrasound solutions to visualize and quantify critical clinical data for improved outcomes and reduced costs in new surgical applications. 

Leadership Overview

David Narrow
CEO

Devin O’Brien-Coon, MD, MSE
President and CMO

Harish Hiriyannaiah, PhD
CTO

Xin (Ben) Kang, PhD
Director of Research & Development

Gerry Buss, RAC
Director of Regulatory Affairs

Michelle Zwernemann
Director of Quality and Operations

Products/Services

Sonavex was formed to develop EchoSure to detect clots earlier and more reliably than existing modalities, to enable successful salvage of reconstructed tissue. The two-part solution consists first of an absorbable marker placed underneath the vessels at the surgical site (EchoMark) and ultrasound with custom software (EchoSure) to automatically collect and calculate blood flow data. This makes it possible for nurses without specialized sonographic training to monitor for clot formation during their current routine once-per-hour examinations using a point-of-care ultrasound. EchoSure analyzes and quantifies flow trends, supporting early clot detection prior to complete blockage.

Portable%20Echo.png

 

For more information, visit http://www.sonavex.com/